MESOBLAST LTD- SPON ADR (MESO)

US5907174016 - ADR

16.76  +4.51 (+36.82%)

Premarket: 13.7 -3.06 (-18.26%)

Fundamental Rating

2

MESO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. MESO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MESO is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MESO has reported negative net income.
MESO had a negative operating cash flow in the past year.
In the past 5 years MESO always reported negative net income.
In the past 5 years MESO always reported negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of -13.14%, MESO belongs to the best of the industry, outperforming 85.66% of the companies in the same industry.
MESO's Return On Equity of -18.31% is amongst the best of the industry. MESO outperforms 86.55% of its industry peers.
Industry RankSector Rank
ROA -13.14%
ROE -18.31%
ROIC N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MESO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MESO has been increased compared to 1 year ago.
Compared to 5 years ago, MESO has more shares outstanding
MESO has a worse debt/assets ratio than last year.

2.2 Solvency

MESO has an Altman-Z score of 4.13. This indicates that MESO is financially healthy and has little risk of bankruptcy at the moment.
MESO's Altman-Z score of 4.13 is fine compared to the rest of the industry. MESO outperforms 78.41% of its industry peers.
MESO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MESO (0.21) is worse than 69.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 4.13
ROIC/WACCN/A
WACC11.48%

2.3 Liquidity

MESO has a Current Ratio of 1.18. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.18, MESO is doing worse than 84.78% of the companies in the same industry.
A Quick Ratio of 1.18 indicates that MESO should not have too much problems paying its short term obligations.
MESO has a worse Quick ratio (1.18) than 83.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.15% over the past year.
Looking at the last year, MESO shows a very negative growth in Revenue. The Revenue has decreased by -21.32% in the last year.
Measured over the past years, MESO shows a very negative growth in Revenue. The Revenue has been decreasing by -18.80% on average per year.
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.08%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%17.53%

3.2 Future

MESO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.02% yearly.
MESO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.90% yearly.
EPS Next Y-2.17%
EPS Next 2Y6.67%
EPS Next 3Y33.02%
EPS Next 5YN/A
Revenue Next Year51.61%
Revenue Next 2Y160.69%
Revenue Next 3Y316.79%
Revenue Next 5Y150.9%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MESO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

MESO's earnings are expected to grow with 33.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y33.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MESO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (12/19/2024, 8:02:21 PM)

Premarket: 13.7 -3.06 (-18.26%)

16.76

+4.51 (+36.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2024-11-20/amc
Earnings (Next)N/A N/A
Inst Owners1.35%
Inst Owner Change4.12%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.91B
Analysts82.86
Price Target11.89 (-29.06%)
Short Float %0.17%
Short Ratio6.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.04%
PT rev (3m)65.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)0%
EPS NY rev (3m)5.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 324.23
P/FCF N/A
P/OCF N/A
P/B 3.98
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-3.97
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.05
BVpS4.21
TBVpS-0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.14%
ROE -18.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z 4.13
F-Score4
WACC11.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.22%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.08%
EPS Next Y-2.17%
EPS Next 2Y6.67%
EPS Next 3Y33.02%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%17.53%
Revenue Next Year51.61%
Revenue Next 2Y160.69%
Revenue Next 3Y316.79%
Revenue Next 5Y150.9%
EBIT growth 1Y-6.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.2%
EBIT Next 3Y80.34%
EBIT Next 5YN/A
FCF growth 1Y23.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.41%
OCF growth 3YN/A
OCF growth 5YN/A